kayhan.ir

News ID: 78824
Publish Date : 20 May 2020 - 21:57

Trump Attacks Study, Defends Using Malaria Drug

WASHINGTON (AP) — President Donald Trump emphatically defended himself against criticism from medical experts that his announced use of a malaria drug against the coronavirus could spark wide misuse by Americans of the unproven treatment with potentially fatal side effects.
Trump’s revelation a day earlier that he was taking hydroxychloroquine caught many in his administration by surprise and set off an urgent effort by officials to justify his action. But their attempt to address the concerns of health professionals was undercut by the president himself.
He asserted Tuesday without evidence that a study of veterans raising alarm about the drug was "false” and an "enemy statement,” even as his own government warned that the drug should be administered for COVID-19 only in a hospital or research setting.
"If you look at the one survey, the only bad survey, they were giving it to people that were in very bad shape,” Trump said. That was an apparent reference to a study of hundreds of patients treated by the Department of Veterans Affairs in which more of those in a group who were administered hydroxychloroquine died than among those who weren’t.
"They were very old. Almost dead,” Trump said. "It was a Trump enemy statement.” During a Cabinet meeting, he elicited a defense of his practice from other officials, including VA Secretary Robert Wilkie, who noted the study in question wasn’t conducted by his agency.
But the drug has not been shown to combat the virus in a multitude of other studies as well. Two large observational studies, each involving around 1,400 patients in New York, recently found no COVID benefit from hydroxychloroquine. Two published last week in the medical journal BMJ reached the same conclusion.
No large, rigorous studies have found the drug safe or effective for preventing or treating COVID-19.
Trump said he decided to take hydroxychloroquine after two White House staffers tested positive for the disease, but he already had spent months promoting the drug as a potential cure or preventive despite the cautionary advice of many of his administration’s top medical professionals.
"This is an individual decision to make,” Trump told reporters during a visit to Capitol Hill to meet with Senate Republicans. He later claimed, "It’s gotten a bad reputation only because I’m promoting it.”